This page is meant to provide a quick glimpse at the schedule of sessions and events that will occur during the 2020 SOT Annual Meeting and ToxExpo. As information becomes available and activities are finalized, they will be added to this page. Full details and information on the sessions and events listed on this page are available as part of the Online Planner on the “Program Details” web page. A printable PDF of the Program Overview will be available in February 2020.
SOT Regional Chapter, Special Interest Group and Specialty Section meetings, luncheons, receptions, mentoring events, and officer meetings occur at various times throughout the week. Use the “Session or Activity Type” filter in the Online Planner to view desired events.
IAT Innovations in Applied Toxicology ITS Innovations in Toxicological Sciences
Mechanistic Read-Across of Chemical Toxicants Based on Big Data ITS
Individual-, Community-, and Population-Level Environmental-Associated Attributes of Disparate Health Outcomes in Vulnerable Populations
The Epidemic of Chronic Kidney Disease of Unknown Etiology in Agricultural Communities
11:00 AM to 12:30 PM
Aircraft Cabin Fume Events: Is There a Toxicological Explanation?
Globally Harmonized Guidance for Dose-Response Analysis and Derivation of Health-Based Guidance Values for Chemicals in Food—Part I: What’s New?
Impacts on Human Health of Sunscreen Active Ingredients Used to Filter Ultraviolet Light
11:30 AM to 12:45 PM
IN VITRO TOXICOLOGY LECTURE AND LUNCHEON FOR STUDENTS (Ticket Required)
Computational Intelligence: Building “Smart Models” for Toxicology in the Era of Big Data
Lecturer: Thomas B. Knudsen, US EPA/CCTE, Research Triangle Park, NC. Supported by: An Educational Grant from the Colgate-Palmolive Company
1:00 PM to 2:00 PM
Precisely Practicing Medicine from 700 Trillion Points of Data
Speaker: Atul Butte, University of California San Francisco, San Francisco, CA.
Dr. Butte is a pioneer in the analysis of big data, using these data to gain new insights into diseases and their treatment. The promises of precision medicine are dependent on the appropriate analysis of large datasets. Dr. Butte will tell us about his group’s efforts to organize and gain insight from health records, leading to better therapeutic choices. He also will describe new methods for teaching intelligence, both real and artificial, for better medical practice.”
— George P. Daston Scientific Program Committee Chair
Evolving Technologies for Determination of Biotherapeutic Specificity
Genome Editing in Drug Discovery: Using the Cas9 Protein to Explore Target-Mediated Toxicity
Bringing Advances in Risk Science into Regulatory Decisions: Applying Data-Driven Uncertainty Analysis
Globally Harmonized Guidance for Dose-Response Analysis and Derivation of Health-Based Guidance Values for Chemicals in Food—Part II: Intuitive Demonstrations
Single Cell Applications in Mechanistic Toxicology ITS
The More, the Better? Single Biomarkers, Panels, and/or Composite Biomarkers to Characterize Organ Injury
Variety Is the Life of Spice: The Clinical Toxicology of Synthetic Cannabinoids
4:45 PM to 6:00 PM
Individual Toxicity Is the Future of Risk Assessment
SOT Debater: Syril D. Pettit, HESI, Washington, DC.
EUROTOX Debater: Alan R. Boobis, Imperial College London, London, United Kingdom.
Tuesday, March 17
6:00 AM to 7:00 AM
Past Presidents' 5K Fun Run/Walk
8:00 AM to 10:45 AM
SOCIETY OF TOXICOLOGY AND JAPANESE SOCIETY OF TOXICOLOGY SYMPOSIUM
Oxidative Stress in Multiple Manifestations of Toxicity
JSOT Speakers: Yoshito Kumagai, University of Tsukuba, Tsukuba, Japan; and Yoshiro Saito, Tohoku University, Sendai, Japan.
SOT Speakers: Alicia R. Timme-Laragy, University of Massachusetts Amherst, Amherst, MA; and Dean P. Jones, Emory University School of Medicine, Atlanta, GA.
Cellular Recovery and Resilience: A New Perspective on Toxicity Testing
Cyanide as a Chemical Threat: Finding Better Antidotes IAT
Electronic Cigarettes and Cardiovascular Toxicity: New Friend or Old Foe?
Environmental Exposure and Health Effects of Organophosphate Esters
Quantitative and Translational Systems Toxicology: Improving Drug Safety from Preclinical to Clinical Outcomes ITS
Human-Relevant Carcinogenicity Testing: Tools for Cancer Assessment in 2020 and Beyond
Using Human Genetics to Aid in Safety Assessment of Therapeutics
Understanding Three Fundamental Quantitative Principles Is a Prerequisite for Improving Toxicological Science and Risk Assessment
Lecturer: Wout Slob, Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Bilthoven, Netherlands.
11:00 AM to 12:20 PM
Novel Uses of Analytical Platforms for Efficacy/Safety Biomarker Selection to Improve De-risking of Therapeutics
EDUCATION-CAREER DEVELOPMENT SESSION
Next-Generation Toxicologist Training through Innovative Summer Internships
12:30 PM to 1:30 PM
PLENARY KEYNOTE MEDICAL RESEARCH COUNCIL (MRC) LECTURE
Lecturer: Dame Amanda Fisher, MRC London Institute of Medical Sciences, London, United Kingdom.
1:30 PM to 4:15 PM
Human Stem Cell–Derived Test Systems as Alternative Approaches for Developmental Neurotoxicity (DNT) Evaluation: Research and Regulatory Perspectives
Improving Our Understanding of Toxicant Metabolism and Cytochrome P450s Using Novel Knockout Models and High-Throughput Methods
New Frontiers in Dynamic Toxicology
Parental Cannabis Exposure and Long-Term Neurobehavioral Deficits in Offspring
2:00 PM to 3:00 PM
Trainee Discussion with Medical Research Council (MRC) Lecturer Dame Amanda Fisher (Ticket Required; Limited Seating)
Thursday, March 19
8:30 AM to 11:15 AM
Application of RISK21 Framework in Regulatory-Based Decision-Making: From Business Decisions to Prioritization to Risk Assessment
Chemical Probes in Toxicology: From Defining Exposures to Identifying Novel Toxicity and Druggable Targets
Express Yourself (or Not . . .): The Nonclinical Safety of Oligonucleotide Therapeutics
Identifying and Modeling Gene-Environment Interactions in Neurological Diseases Associated with Metal Exposure: Challenges and Recent Advances
Protecting the Force: Examining the Hazards of Military Service from the Bench and the Battlefield
Cannabidiol Science, Safety, and Societal Impacts: Where Do We Stand? IAT
Have In Vitro Teratogenicity Assessments Come of Age in the Pharmaceutical Industry?
Immune-Mediated Adverse Drug Reactions: State-of-the-Art Learnings from Preclinical and Clinical Drug Development IAT